Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis

Status Recruiting

Clinical Trial Summary

These studies are designed to assess the synergistic efficacy of topical 0.1% triamcinolone cream paired with 40,000 IU of oral vitamin D3 daily in treating mild to moderate psoriasis. The study is designed to have all subjects treated with triamcinolone cream (TAC) for 4 weeks, then will be randomized 1:1 into vitamin D3 or placebo for an additional 12 weeks. At that time, the study will become open-label and all subjects will be placed on (or continue) vitamin D3 for an additional 12 weeks. The study will take place over 28 weeks total.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04036188
Study type	Interventional
Source	Wright State University
Contact	Manager, Clinical Research Operations
Phone	937-245-7500
Email	pturesearch@wrightstatephysicians.org
Status	Recruiting
Phase	Early Phase 1
Start date	October 16, 2019
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01194219` - Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis	Phase 3
Recruiting	`NCT06030076` - A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
Completed	`NCT04263610` - Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy	Phase 4
Completed	`NCT02601469` - Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis	Phase 2
Completed	`NCT05600036` - A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis	Phase 2
Completed	`NCT05375955` - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.	Phase 2
Completed	`NCT03614078` - A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis	Phase 2
Not yet recruiting	`NCT05036889` - A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes.	N/A
Completed	`NCT04603027` - A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis	Phase 2
Completed	`NCT03638258` - The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis	Phase 2
Completed	`NCT02881346` - Efficacy and Tolerability of Enstilar® in Daily Practice
Recruiting	`NCT02611349` - Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis	Phase 3
Completed	`NCT02251678` - Evaluate the Effect of Elimune Capsules	Phase 1
Completed	`NCT01987843` - Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis	Phase 2
Terminated	`NCT01708629` - Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects	Phase 3
Completed	`NCT01230138` - Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis	Phase 2
Withdrawn	`NCT00747032` - To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis	Phase 3
Completed	`NCT00581100` - Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis	Phase 4
Suspended	`NCT01228656` - Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate	Phase 2
Completed	`NCT00540618` - A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis	Phase 2